Navigation Links
Experimental TB drug effective against resistant and latent mycobacterium tuberculosis

An experimental tuberculosis drug may be effective against not only multi drug-resistant forms of the disease but could also be the first compound to treat the latent stage of infection as well. Researchers report their results today at the 2006 ASM Biodefense Research Meeting.

"The class of which this compound is the lead has a very different mechanism of action from any other drug currently used to treat tuberculosis. We have identified no cross resistance with existing drugs. Every isolate we have tested so far has been susceptible to this compound," says Nicole Parrish of Johns Hopkins Medical School, a lead researcher on the study.

"This compound (FAS20013) appears to be a potential new drug for treating all forms of tuberculosis, even drug-resistant and latent infections," says Albert Owens, President of FASgen, Inc., the company working to bring the drug to market.

The potent killing activity of FAS20013 is directed specifically against slow growing mycobacteria that cause the disease rather than at a broad array of non-pathogenic organisms, which merely enhances the emergence of drug- resistant strains. No resistance has been encountered to FAS20013 in clinical isolates,. The short-term killing power of FAS20013 is greater than currently used drugs; for example, FAS20013 will kill more organisms in a 4-hour exposure than isoniazid or rifampin can during a 12- to 14-day exposure.

Multiple drug-resistant tuberculosis (MDR-TB) has a fatality rate of 20 to 80 percent. In the United States if a person fails to respond to all therapies and doctors cannot bring the active infection under control, that person must be quarantined indefinitely to prevent the spread of the drug-resistant infection in the population. In the most extreme cases, part of the lung may be surgically removed. It is estimated the cost of treating a single case of MDR-TB can be as much as $250,000.

What makes this drug candidate even more promis
'"/>

Source:American Society for Microbiology


Page: 1 2

Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. Experimental shingles vaccine proves effective in nationwide study
3. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
4. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
5. Experimental RNA-based drug kills prostate cancer cells effectively and safely
6. Experimental vaccine protects lab animals against several strains of H5N1
7. Experimental vaccine protects mice against deadly 1918 flu virus
8. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
9. Experimental vaccine given during pregnancy reduces stillbirths from common virus
10. Combination therapy boosts effectiveness of telomere-directed cancer cell death
11. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
Post Your Comments:
(Date:7/25/2008)... translate basic science discoveries into the clin...researchers at the Medical College of Wisconsin, i...H) identified reasons why clinical science grant ...an basic science grant applications to the NIH. Th...e American Journal of Medicine . , In collaborat...
(Date:7/25/2008)...and Industry specialists from 22 countries are sha... species, such as mustard, radish, or rapeseed, t...nown as biofumigation. ," Brassica plants natur...hogens, principally isothiocyanates (ITCs), which ...n mustard or horseradish," says CSIRO,s Dr John Ki...
(Date:7/25/2008)...rned ,green, can potentially contain a naturally o... a risk to public health according to a review pap...Journal of the Science of Food and Agriculture (J...way the ,green, affected area is enough to elimina...per also suggests that the levels of GA in potatoe...
(Date:7/24/2008)... team led by Massachusetts General Hospital (MGH) ...r genomic research and medicine a robust method f...rticular DNA sequences for inactivation or repair....esearchers describe an efficient, publicly availab...ases (ZFNs), which can be used to induce specific ...
Breaking Biology News(10 mins):New study spotlights National Institutes of Health grant outcomes for clinical research 2Consortium develops new method enabling routine targeted gene modification 2Transave Announces Positive Phase II Results for Once Daily Arikace 28TM 29 in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Inf 2420 1Transave Announces Positive Phase II Results for Once Daily Arikace 28TM 29 in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Inf 2420 2Transave Announces Positive Phase II Results for Once Daily Arikace 28TM 29 in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Inf 2420 3Transave Announces Positive Phase II Results for Once Daily Arikace 28TM 29 in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Inf 2420 4Transave Announces Positive Phase II Results for Once Daily Arikace 28TM 29 in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Inf 2420 5Drug Addiction Explained by Drug Addiction Center 21785 1Drug Addiction Explained by Drug Addiction Center 21785 2Humour is Fundamental to our Success as a Species 5978 1Humour is Fundamental to our Success as a Species 5978 2Road pollution blamed for higher allergy risk in kids 21782 1Road pollution blamed for higher allergy risk in kids 21782 2
...r cells display a dramatic reduction of cancer-cau...to activate the expression of protective microRNAs...d in the June issue of Cancer Cell, demonstrates t...lso impact regulatory RNAs that may function as tu...el strategy for treating human cancers. , DNA meth...
... by Dr. Sara Melville at the University of Cambrid...can sleeping sickness has evolved an unusual chrom...tation. In this parasite, the chromosomes are hig...d variable regions that connect the chromosome end...some cases comprising 75% of the total chromosome ...
...is month,s European Journal of Nutrition demonstra...s in non-obese postmenopausal women and the dose-d...rly SoyLife®. These findings support previous scie...-menopausal women. , According to the authors of t...rienced by about one in three postmenopausal women...
...ld in 1965, rock star Pete Townshend wrote the lin... Generation" that launched his band, the Who, onto...y suggests that Townshend may have fallen victim t...t days of people,s lives occur when they,re young....nd older people think that young people are happie...
Other Biology News:Activation of microRNA inhibits cancer gene in human cancer cells 2DNA to the defense 2New research: Soy germ isoflavones reduce bone loss 2Hope I die before I get old? 2Hope I die before I get old? 3Hope I die before I get old? 4
(Date:7/25/2008)...e-FirstCall/ -- China Medical,Technologies, Inc. (...ased,medical device company that develops, manufac...ducts and high intensity focused ultrasound tumor,...version rate for the,Company,s US$150 million outs... due November 2011 (the ,Convertible Notes,)., ...
(Date:7/24/2008)...wswire-FirstCall/ -- Coherent, Inc.,(Nasdaq: COH...financial,results after the market close and host ... 2008 results scheduled for July 30, 2008 at 4:30 ...e Internet and can be accessed,at either http://w...s.com .,For those who are not available to listen ...
(Date:7/24/2008)...ire-FirstCall/ -- InterMune, Inc.,(Nasdaq: ITMN )...er 2008,financial results and provide a business u...ern time. A live conference call and webcast will ...hat same day., To access the live teleconference,...tional), conference ID# 57393097. To access the,we...
(Date:7/24/2008)...an to Help Spearhead Growth, PITTSBURGH, July 24 ...http://www.hmsinc.com ), pioneering health informa...l has been appointed vice president, sales., Dock...les, sales,management and product distribution for...and pharmaceutical companies., "Karen has an impr...
Breaking Biology Technology:China Medical Technologies Adjusts Conversion Rate of Convertible Notes 2InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31 2Health Monitoring Systems Appoints Karen S. Dockrell As VP, Sales 2
...ng passages of Alice in Wonderland , you should. ... accurate description of most modern IT projects. ...for a very important date, always just out of reac...tunity, and unavailable for any meaningful dialog....ity of a workload rushing by ones ears. And then ...
...ombay firm , Milwaukee OnCourse Technologies ,...es, announced on Tuesday they have signed a term s...ons Software , an India-based firm. Both firms are... the software for manufacturers, while Cimtronics...s. The deal is expected to be done within the next...
... 25 percent of online marketers track their pay-pe...h, presented at the Jupitermedias 2004 Search Engi...ree quarters of pay-per-click (PPC) marketers who ... them run their course without any ongoing analysi...ers often track click-throughs in and manage their...
...nksgiving to New Year,s), it,s common for people t...nderstandably, people become busy with family and ...,Contrary to popular belief, the holiday season is...s, holiday cards and companies still in hiring mod..., companies and networking groups generally hold h...
Other Biology Technology:The IT drug Just say no? 2The IT drug Just say no? 3Tech Digest: OnCourse, Menasha, Fiserv, Rockwell 2How to make pay-per-click ad campaigns pay off 2Contrary to popular belief, holidays are an important time to network 2Contrary to popular belief, holidays are an important time to network 3
Request Info
supplied with 10x reaction buffer
from yeast/leuconostoc overproducer ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: NADP 1-oxidoreductase EC 2.7.1.1/1.1.1.49. One unit of HK will phosphorylate 1 mol of D-glucose in 1 min
Request Info
Biology Products: